• Hypercoagulable states 
en To content Full text of article

Hypercoagulable states 

PERINATOLOGIYA I PEDIATRIYA. 2016.2(66):25-27; doi 10.15574/PP.2016.66.25 
 

Hypercoagulable states 
 

Ishchenko A. I., Demenina N. K., Milevskiy A. V.

SI «Institute of Pediatrics, Obstetrics and Gynecology NAMS Ukraine», Kiev 
 

Pregnancy causes a number of physiological changes, which affect the hematologic parameters, either directly or indirectly. The main reason for the increased risk of thromboembolism during pregnancy is hypercoagulability, which is likely to occur in order to protect a woman from bleeding due to miscarriage and childbirth. Woman's risk of thromboembolism during pregnancy and the postpartum period is increased by 4–5 times. Eighty percent of thromboembolic complications during pregnancy are venous, with a frequency of 0.49 to 1.72 per 1000 pregnancies. Risk factors include a history of thrombosis, hereditary and acquired thrombophilia, maternal age over 35, some medical conditions, as well as various complications of pregnancy and childbirth. Determining the cause hypercoagulability may help in choosing the duration and treatment of thrombosis. In the literature, there is no sufficient data of tests involving the use of anticoagulants during pregnancy. The purpose of this scientific review is a logical definition and assistance in choosing the treatment tactics hypercoagulable syndrome. 
 

Key words: hypercoagulable states, thrombophilia, pregnancy, haemostasis, antiphospholipid syndrome, bleeding. 
 

REFERENCES

1. Beller FK, Ebert C. 1982. The coagulation and fibrinolytic enzyme systems in normal pregnancy and the puerperium. Eur J Obstet Gynecol Reprod Biol. 13: 177—97.

2. Bick RL, Kaplan H. 1998. Syndromes of thrombosis and hypercoagulability. Med Clin North Am. 82: 409—458.

3. Bonnar J. 1987. Haemostasis and coagulation disorders in pregnancy. Haemostasis and Thrombosis. Bloom AL, Thomas DP editors. Edinburgh, Churchill Livingstone: 570—84.

4. Bremme K, Ostlund E, Almqvist I et al. 1992. Enhanced thrombin generation and fibrinolytic activity in the normal pregnancy and the puerperium. Obstet Gynecol. 80: 132—7.

5. Clark P, Brennand J, Conkie JA et al. 1998. Activated protein C sensitivity. Protein C, protein S and coagulation in normal pregnancy. Thrombhaemost. 79: 1166—70.

6. Den Heijer M, Rosendaal FR, Blom HJ et al. 1998. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 80: 874—877.

7. De Stefano V, Martinelli I, Mannucci PM et al. 1999. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 341: 801—806.

8. Douglas JT, Shah M, Lowe GD et al. 1982. Plasma fibrinopeptide A and b-thromboglobulin in pre-eclampsia and pregnancy hypertension. Thromb Haemost. 47: 54—5.

9. Fitzgerald DJ, Mayo G, Catella F et al. 1987. Increased thromboxane biosynthesis in normal pregnancy is mainly derived from platelets. Am J Obstet Gynecol. 157: 325—30.

10. Francalanci I, Comeglio P, Liotta AA et al. 1995. D-dimer concentrations during normal pregnancy, as measured by ELISA. Thromb Res. 78: 399—405.

11. Gerbasi FR, Bottoms S, Farag A, Mammen E. 1990. Increased intravascular coagulation associated with pregnancy. Obstet Gynecol. 75: 385—9.

12. Gordon O, Almagor Y, Fridler D et al. 2014. De novo neonatal antiphospholipid syndrome: a case report and review of the literature. Semin Arthritis Rheum. 13: S0049—0172(14)00051—1.

13. Greer ІA. 1994. Haemostasis and thrombosis in pregnancy. Haemostasis and thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, Editors. 3rd ed. Edinburgh, Churchill Livingstone: 987—1015.

14. Letsky EA. 1985. Coagulation Problems During Pregnancy. Churchill Livingstone, Edinburgh.

15. Miyakis S, Lockshin MD, Atsumi T et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 4;2: 295—306.

16. Salomon O, Steinberg DM, Zivelin A et al. 1999. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol. 19: 511—518.

17. Sciascia S, Sanna G, Khamashta MA et al. 2014. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis. 18: 205—663.

18. Singh AK. 2000. Lupus nephritis and the anti-phospholipid antibody syndrome in pregnancy. Kidney International. 58;5: 2240—2254.

19. Stirling Y, Woolf L, North WR et al. 1984. Haemostasis in normal pregnancy. Thromb Haemost. 52: 176—82.

20. Wallemburg HCS, Van Kessel PH. 1978. Platelet lifespan in normal pregnancy as determined by a non-radioisotopic technique. Br J Obstet Gynaecol. 85: 33—6.

Содержание журнала Full text of article